Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases

11. januar 2017 opdateret af: Mayo Clinic

Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study

RATIONALE: Percutaneous cryoablation may help relieve pain caused by bone metastases.

PURPOSE: This clinical trial is studying the side effects and how well percutaneous cryoablation works in treating patients with painful bone metastases.

Studieoversigt

Detaljeret beskrivelse

OBJECTIVES:

  • To confirm the safety of percutaneous cryoablation in the palliative treatment of patients with painful bone metastases.
  • To determine the benefits of cryoablation of painful bone metastases by assessing pain intensity using a standardized Cleeland Brief Pain Inventory (BPI) and quality of life using a standardized SF-8 both before and after treatment.
  • To determine the secondary benefits of cryoablation of painful bone metastases by assessing change in analgesic use following therapy.
  • To determine the level of anesthesia required for cryoablation with a baseline level of conscious sedation planned for each treatment.

OUTLINE: This is a multicenter study.

Patients undergo percutaneous cryoablation to one or two sites of metastatic disease using the Endocare Cryocare system. Patients with a good initial response to treatment (≥ 2 decrease in pain intensity rating on the Brief Pain Inventory) who develop recurrent pain at the same site or a new painful site ≥ 1 month after initial treatment may undergo one additional cryoablation treatment.

Patients complete pain and quality of life questionnaires periodically.

After completion of study treatment, patients are followed periodically for 2 years.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224
        • Mayo Clinic - Jacksonville
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109-0942
        • University of Michigan Comprehensive Cancer Center
      • Detroit, Michigan, Forenede Stater, 48201-1379
        • Barbara Ann Karmanos Cancer Institute
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic Cancer Center
    • New York
      • New York, New York, Forenede Stater, 10021
        • Memorial Sloan-Kettering Cancer Center
      • New York, New York, Forenede Stater, 10016
        • NYU Cancer Institute at New York University Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104-4283
        • Abramson Cancer Center of the University of Pennsylvania
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02912
        • Brown University School of Medicine
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792-6164
        • University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
      • Milwaukee, Wisconsin, Forenede Stater, 53215
        • Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 120 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed metastatic solid tumor involving or abutting bone (index lesion)

    • If the nature of the metastatic disease has been previously documented, index lesion to be treated does not require further documentation (i.e., biopsy)
  • Pain either refractory to standard care (chemotherapy, radiotherapy, surgery, or analgesics) or patient is considered a poor candidate for conventional therapies

    • Radiation oncology consult is required if the patient is considered clinically to be a candidate for conventional palliative radiotherapy
    • Surgical oncology consult is required if the patient is considered clinically to be a candidate for conventional surgical treatment or is considered at risk for complications resulting from potential fracture
  • Initial pain score ≥ 4 on a scale of 0-10 for the question "Please rate your pain by circling the one number that best describes your pain at its worst in the past 24 hours" on the Cleeland Brief Pain Inventory

    • Pain from ≤ 2 sites of metastatic disease
  • No lesions with evidence for impending fracture involving a weight-bearing bone (> 50% loss of cortical bone at the site)

PATIENT CHARACTERISTICS:

  • Life expectancy ≥ 2 months
  • Platelet count ≥ 75,000/mm³
  • ANC > 1,500/mm³ (for patients who have recently been treated with chemotherapy)
  • INR ≤ 1.2
  • Not pregnant or nursing
  • Negative pregnancy test

PRIOR CONCURRENT THERAPY:

  • More than 3 weeks since prior radiotherapy
  • More than 3 weeks since initiation of a new chemotherapy regimen, including bisphosphonates
  • More than 7 days since prior antiplatelet medications or clopidogrel
  • More than 3 days since prior acetylsalicylic acid (aspirin), ibuprofen, or other NSAIDs
  • No prior treatment of the portion of a lesion within 0.5 cm of the spinal cord or brain, within 0.5 cm of a large abdominal vessel such as the aorta or inferior vena cava, or within 1 cm of bowel or bladder
  • No prior radiofrequency ablation for pain palliation of the same lesion
  • No concurrent regular or low molecular weight heparin or other anticoagulants

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Maskning: Ingen (Åben etiket)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Average difference in pre- and post-treatment worst pain score in a 24-hour period at week 8

Sekundære resultatmål

Resultatmål
Average difference in pre- and post-treatment worst pain score in a 24-hour period, average pain score, and pain relief score at 6, 12, and 24 months
Average amount of pain per patient over the observation period as represented by the area under the curve (AUC) constructed from weekly pain scores on a visual-analogue scale using a score of 0-10
Percentage of patients who are able to reduce analgesic medications

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studiestol: Matthew R. Callstrom, MD, PhD, Mayo Clinic

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. november 2003

Primær færdiggørelse (Faktiske)

1. februar 2013

Studieafslutning (Faktiske)

1. februar 2013

Datoer for studieregistrering

Først indsendt

1. februar 2008

Først indsendt, der opfyldte QC-kriterier

1. februar 2008

Først opslået (Skøn)

6. februar 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

12. januar 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. januar 2017

Sidst verificeret

1. januar 2017

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • MC03C3
  • MAYO-MC03C3

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Smerte

Kliniske forsøg med spørgeskemaadministration

3
Abonner